Myriad Genetics (MYGN) Total Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has reported Total Liabilities for 17 consecutive years, with $336.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 11.65% year-over-year to $336.3 million; the TTM figure through Mar 2026 stood at $336.3 million (up 11.65% YoY), while the FY2025 annual figure was $338.6 million, up 3.71% from the prior year.
• Total Liabilities retreated to $336.3 million in Q1 2026 per MYGN's latest filing, from $338.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $465.7 million in Q3 2023 and bottomed at $262.8 million in Q2 2022.
• Historically, Total Liabilities has averaged $340.2 million across 5 years, with a median of $336.3 million in 2026.
• Annual changes were most pronounced in 2022 — Total Liabilities slumped 42.61% — and 2023, when it jumped 71.99%.
• Myriad Genetics' Total Liabilities stood at $312.9 million in 2022, then rose by 16.11% to $363.3 million in 2023, then dropped by 10.13% to $326.5 million in 2024, then grew by 3.71% to $338.6 million in 2025, then decreased by 0.68% to $336.3 million in 2026.
• Business Quant data shows MYGN's Total Liabilities at $336.3 million in Q1 2026, $338.6 million in Q4 2025, and $355.3 million in Q3 2025.